Early Economic Assessment of Faecal Microbiota Transplantation for Patients with Urinary Tract Infections Caused by Multidrug-Resistant Organisms
Authors:
- Olivia Dybro BaekOBOlivia Dybro Baek
- Camilla K. HjermitslevCHCamilla K. Hjermitslev
- Line DyreborgLDLine Dyreborg
- Simon M. D. BaunwallSBSimon M. D. Baunwall
- Katrine L. HøyerKHKatrine L. Høyer
- Nina RågårdNRNina Rågård
- Lianna H. HammekenLHLianna H. Hammeken
- Johan V. PovlsenJPJohan V. Povlsen
- Lars H. EhlersLELars H. Ehlers
- Christian Lodberg HvasCHChristian Lodberg Hvas
Open Access
- 16 April 2023
- journal article
- research article
- Published by Springer Nature in Infectious Diseases and Therapy
- Vol. 12 (5) , 1429-1436
Abstract
Introduction The use of faecal microbiota transplantation (FMT) to eradicate intestinal carriage of multidrug-resistant organisms (MDRO) has been described in case reports and small case series. Although few in numbers, these patients suffer from recurrent infections that may exacerbate both the patients’ comorbidities and their healths. In the current study, we hypothesized that FMT for MDRO-related urinary tract infections (UTIs) reduces hospitalisations and associated costs. Methods In a cohort of patients referred for FMT from 2015 to 2020, we selected all patients who had consecutively been referred for eradication of MRDO carriage with UTIs. An early economic assessment was performed to calculate hospital-related costs. The overall study cohort was registered at ClinicalTrials, study identifier NCT03712722. Results We consecutively included five patients with UTIs caused by MDROs. Four of the patients were renal transplant recipients. Patients were followed for median 126 days (range 60–320), where the follow-up duration for each patient was aligned with the number of days from the first UTI to FMT. The median number of UTIs per patient dropped from 4 to 0. Investigating hospital costs, hospital admission days dropped by 87% and monthly hospital costs by 79%. Conclusions FMT was effective in reducing the occurrence of UTIs and mediated a marked reduction in hospital costs. We suggest that this strategy is cost-effective. Trial Registration ClinicalTrials, study identifier NCT03712722. Graphical AbstractKeywords
Funding Information
- Innovationsfonden (8056-00006B)
- Novo Nordisk Fonden (NNF22OC0074080)
This publication has 14 references indexed in Scilit:
- Impact of multi-drug resistant bacteria on economic and clinical outcomes of healthcare-associated infections in adults: Systematic review and meta-analysisPLOS ONE, 2020
- Antimicrobial Resistance: Implications and CostsInfection and Drug Resistance, 2019
- Faecal Microbiota Transplantation Eradicated Extended-Spectrum Beta-Lactamase-Producing Klebsiella pneumoniae from a Renal Transplant Recipient with Recurrent Urinary Tract InfectionsCase Reports in Nephrology and Dialysis, 2019
- A 5-day course of oral antibiotics followed by faecal transplantation to eradicate carriage of multidrug-resistant Enterobacteriaceae: a randomized clinical trialClinical Microbiology and Infection, 2019
- Cost savings following faecal microbiota transplantation for recurrent Clostridium difficile infectionTherapeutic Advances in Gastroenterology, 2019
- Impact of Urinary Tract Infections in Kidney Transplant Recipients: A 4-Year Single-Center ExperienceTransplantation Proceedings, 2018
- Fecal microbiota transplantation in a kidney transplant recipient with recurrent urinary tract infectionInfection, 2018
- Recruitment of feces donors among blood donors: Results from an observational cohort studyGut Microbes, 2018
- Fecal Microbiota Transplantation for Recurrent Clostridium difficile Infection Reduces Recurrent Urinary Tract Infection FrequencyClinical Infectious Diseases, 2017
- Fecal Microbiota Transfer for Multidrug-Resistant Gram-Negatives: A Clinical Success Combined With Microbiological FailureOpen Forum Infectious Diseases, 2017